Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Influence of Peptide-Based Chelator Sequences on HER2-Targeting Radiopeptide.

Journal of peptide science : an official publication of the European Peptide Society·2026

Same author

<sup>99m</sup>Tc-HYNIC PEGylated Peptide Probe Targeting HER2-Expression in Breast Cancer.

Chemical biology & drug design·2025

Same author

Peptide-drug conjugate designated for targeted delivery to HER2-expressing cancer cells.

Journal of peptide science : an official publication of the European Peptide Society·2024

Same author

Nuclear Localization Signal Enhances the Targeting and Therapeutic Efficacy of a Porphyrin-Based Molecular Cargo: A Systemic In Vitro and Ex Vivo Evaluation.

Molecular pharmaceutics·2024

Same author

Synthesis and <sup>177</sup>Lu Labeling of the First Retro Analog of the HER2-Targeting A9 Peptide: A Superior Variant.

Bioconjugate chemistry·2023

Same author

Assessment of <sup>177</sup> Lu-labeled carboxyl-terminated polyamidoamine (PAMAM) dendrimer-RGD peptide conjugate.

Journal of peptide science : an official publication of the European Peptide Society·2021

Same journal

Comparative Investigation of the Impact of Sodium Citrate Buffers on Lipid Nanoparticles of circRNA or Linear mRNA.

Molecular pharmaceutics·2026

Same journal

Preclinical Evaluation of <sup>177</sup>Lu-Labeled Anti-CLDN18.2 VHH-Fc for Radioimmunotherapy in Gastric Cancer.

Molecular pharmaceutics·2026

Same journal

The Impact of Plasticizer Polarity on the Permeability of Hydroxypropyl Methylcellulose Phthalate Films.

Molecular pharmaceutics·2026

Same journal

Call For Papers: Molecular Understanding and Formulation Design for Peptide Delivery.

Molecular pharmaceutics·2026

Same journal

Done EAZY: An Automated Procedure for <sup>89</sup>Zr-Radiolabeling and Size-Exclusion Chromatography Purification of Nanoliposomal Anticancer Therapeutics.

Molecular pharmaceutics·2026

Same journal

Low-Temperature Hot Melt Extrusion: Solid-State Organization and Mechanical Performance of Lipid Filaments.

Molecular pharmaceutics·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 22, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Cancer Targeting Radiopeptidomimetics in Molecular Nuclear Medicine.

Drishty Satpati^1,2

¹Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai 400085, India.

Molecular Pharmaceutics

|March 13, 2025

Summary

This summary is machine-generated.

Peptides are promising for cancer radiopharmaceuticals, but degrade quickly. Redesigned peptides, or peptidomimetics, offer improved stability and efficacy for cancer detection and treatment.

Keywords:

Cancer Inverso D-peptide Peptidomimetics Retro peptide Retro-inverso rD peptide

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Related Experiment Videos

Last Updated: May 22, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Area of Science:

Biochemistry
Radiopharmaceutical Chemistry
Oncology

Background:

Peptides are ideal ligands for radiopharmaceuticals due to receptor affinity and pharmacokinetic properties.
Natural peptides face limitations like proteolysis, hindering in vivo stability and target uptake, thus restricting clinical application.
Rising cancer incidence necessitates advanced, disease-directed radiopharmaceuticals.

Purpose of the Study:

To review the design strategies for creating metabolically stable peptidomimetics.
To highlight the role of peptidomimetics in enhancing cancer detection and treatment.
To discuss clinically successful radiopeptidomimetics derived from various design approaches.

Main Methods:

Incorporation of D-amino acids (inverso peptidomimetics).
Reversal of D-amino acid sequence (retro-inverso peptidomimetics).
Reversal of L-amino acid sequence (retro peptidomimetics).

Main Results:

Peptidomimetic design strategies significantly improve metabolic stability compared to natural peptides.
Modified peptides demonstrate comparable or enhanced receptor affinity.
Clinically successful radiopeptidomimetics have been developed using these approaches.

Conclusions:

Peptidomimetics offer a viable solution to overcome the limitations of natural peptides in radiopharmaceutical development.
These redesigned peptides are crucial for advancing cancer management through improved diagnostics and therapeutics.
Further development of peptidomimetics holds significant promise for future cancer radiopharmaceutical applications.